MyFinsight
Home
Blog
About
Contact
Issuance of common stock
in connection with...
$162,349K
Proceeds from exercise of
stock options
$174K
Maturities and sales of
investments
$170,599K
Net cash provided by
financing activities
$162,523K
Net cash provided by
investing activities
$11,835K
Canceled cashflow
$158,764K
Net increase in
cash, cash...
$41,972K
Canceled cashflow
$132,386K
Stock-based compensation
$12,087K
Depreciation and
amortization
$2,811K
Noncash lease expense
$1,338K
Other assets
-$657K
Amortization of premiums on
investments, net
-$394K
Prepaid expenses and
other current assets
-$382K
Change in fair value of
equity investments
$170K
Other non-cash items,
net
$82K
Purchases of investments
$158,374K
Purchases of long-lived
assets
$390K
Net cash used in
operating activities
-$132,386K
Canceled cashflow
$17,921K
Net loss
-$125,695K
Accrued liabilities and
other long-term...
-$17,223K
Accounts payable
-$4,226K
Operating lease
liabilities
-$2,273K
Change in estimated
fair value of...
-$890K
Back
Back
Cash Flow
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)
source: myfinsight.com